Anteris Technologies Global Corp. Stock 12‑Month Price Target Cut to $12.84, Implies 93% Upside

Anteris Technologies Global Corp.'s average price target was reduced by analysts from $13.04 to $12.84, with a range of $9.19 to $16. This implies a 93% upside from the Oct. 12 closing price. The consensus rating remains 'Buy' among 6 analysts.

Original reporting
Published Oct 13, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Anteris Technologies Global Corp. Stock 12‑Month Price Target Cut to $12.84, Implies 93% Upside — source image
Decision brief

The 30-second read

Low
01

Why it matters

Minor downward revision suggests limited near‑term price pressure but no material catalyst.

02

Market read

Small analyst downgrade with modest upside potential; unlikely to move market broadly.

03

What to watch

Lack of new company‑specific data; the cut is driven by broader market bias.

Relevance 4/10Novelty 4/10Timing: same-day release

Background

Analyst consensus price target for Anteris Technologies Global Corp. lowered from $13.04 to $12.84.

Market effects

none

none

none

Counterpoint

Price target cuts may reflect short‑term analyst sentiment rather than fundamental shift.

Key entities

  • Anteris Technologies Global Corp.

    Subject of analyst price‑target revision.

Related articles

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.